RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
AI system detects sudden cardiac death risk, identifying thousands more patients annually
medicalxpress - Each year in the U.S., more than 300,000 people die from sudden cardiac arrest, a condition in which the heart's electrical system malfunctions without warning. The medical emergency can kill both high-risk older adults and young athletes with no history …
AI Summary: New AI tools claim to identify far more patients at risk of sudden cardiac death than traditional metrics, detecting subtle patterns invisible to clinicians. Early studies suggest strong sensitivity gains, but experts caution that screening scale‑up, false positives and prospective validation will determine whether the tech saves lives or simply creates more testing.
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
A Ban Won’t Stop Abortion Pill Access, Telehealth Providers Say
Kate Wells / kffhealthnews - As a federal court mulls a case that could result in significant restrictions on a pill used in most abortions, providers say they have alternatives to preserve access even in states with bans in place.
AI Summary: Providers and telehealth advocates warn that banning access won’t stop patients from obtaining abortion pills online. Telemedicine and pharmacy workarounds continue to provide routes for care, underscoring limits of state bans and foreshadowing prolonged legal and practical battles over remote prescribing, cross‑border services, and patient privacy.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Ashok Sebastian Komaranchath: Delighted to Speak at the 5th International Oncology Forum on 20–21 June 2026
oncodaily - Ashok Sebastian Komaranchath, Consultant Medical Oncology and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared on LinkedIn: “I was delighted to speak at the 5th International Oncology Forum […]
AI Summary: The FDA (and HHS) launched Operation TrialBlazer, an initiative to accelerate and modernize clinical development by streamlining trial design, data sharing and regulatory pathways. The program aims to reclaim trial competitiveness and reduce time‑to‑market, promising faster patient access — if stakeholders can agree on what “modernize” actually means.
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
Rebecca Robbins / nytimes - In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
AI Summary: A high‑profile medical journal retracted a paper that claimed cancer immunotherapy is significantly more effective when administered in the morning. The reversal follows scrutiny over methods and data integrity, prompting clinicians to pause any scheduling changes until robust evidence actually materializes.
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.
Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.